Head-to-head evidence
fluticasone propionate vs Fluticasone propionate/salmeterol (Advair HFA)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
fluticasone propionate
Marketed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
The study was randomized and double-blind, included 908 participants, and compared fluticasone-based treatments with placebo. However, its primary measure was a pulmonary-function surrogate rather than a hard clinical or endoscopic outcome, and the registry does not report whether the primary comparison was met.
Next expected readout: September 2027 · NCT07664527 (registry estimate)
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00158834 · Phase 3 · completed
The study randomized 200 children and used double blinding with an active fluticasone comparator. Its primary endpoint was the clinical measure of asthma symptom-free days, but no results are posted, so whether that endpoint was met cannot be determined.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone propionate's landscape · Fluticasone propionate/salmeterol (Advair HFA)'s landscape